German Biotech Company for Biomedicals
German Biotech Company for Biomedicals

The European Commission announced Friday morning that the German company Biotech for Biomedicals will receive 100 million euros from the European investment between you to develop a vaccine against Covid-19 disease.

The Commission added that the German company will use this money for purposes including increasing its production capacity to provide the vaccine as soon as possible, in the event of a successful trial.

According to the commission, BIOTEC is the first European company to start clinical tests of candidate real estate, one of which is an anti-Corona serum. The company began its clinical study in Germany in April and another study followed in the United States last May.

One of the most comprehensive programs in the world is the BIOTEC program, which includes conducting simultaneous trials on four serum candidate materials.

According to data released by the company, which is based in Mainz, last month, the first clinical data on serum tests are expected to be released by the end of this June or July.